4D Molecular Therapeutics, Inc. (NASDAQ:FDMT) Given Average Recommendation of Buy by Brokerages

Shares of 4D Molecular Therapeutics, Inc. (NASDAQ:FDMT – Get Free Report) have earned a consensus rating of “Buy” from the ten analysts that are covering the stock, MarketBeat reports. Ten research analysts have rated the stock with a buy rating. The average 12 month price target among brokerages that have issued ratings on the stock […]

Related Keywords

United States ,Canada ,Scott Bizily ,Nasdaq ,Healthcare Of Ontario Pension Plan Trust Fund ,D Molecular Therapeutics Inc ,Royal Bank ,Goldman Sachs Group ,Barclays ,Goldman Sachs Group Inc ,Redmile Group ,Vanguard Group Inc ,Molecular Therapeutics ,Get Free Report ,Sachs Group ,Ontario Pension Plan Trust Fund ,Vanguard Group ,Molecular Therapeutics Price ,Get Free ,Molecular Therapeutics Daily ,